MORF4L2

Summary

MORF4L2 (mortality factor 4 like 2, HGNC:16849) is a protein-coding gene on chromosome Xq22.2, encoding Mortality factor 4-like protein 2 (Q15014). Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histone H4 and H2A.

Involved in positive regulation of double-strand break repair via homologous recombination and regulation of cell cycle. Located in nucleolus; nucleoplasm; and plasma membrane. Part of NuA4 histone acetyltransferase complex and nucleosome.

Source: NCBI Gene 9643 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 35 total — 3 pathogenic
• MANE Select transcript: NM_012286

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16849
Approved symbol	MORF4L2
Name	mortality factor 4 like 2
Location	Xq22.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0026, MRGX
Ensembl gene	ENSG00000123562
Ensembl biotype	protein_coding
OMIM	300409
Entrez	9643

Gene structure

Transcript identifiers

Ensembl transcripts: 97 — 92 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000360458, ENST00000418819, ENST00000422355, ENST00000433176, ENST00000434230, ENST00000441076, ENST00000442614, ENST00000451301, ENST00000467755, ENST00000474653, ENST00000488331, ENST00000492116, ENST00000498064, ENST00000908311, ENST00000908312, ENST00000908313, ENST00000908314, ENST00000908315, ENST00000908316, ENST00000908317, ENST00000908318, ENST00000908319, ENST00000908320, ENST00000908321, ENST00000908322, ENST00000908323, ENST00000908324, ENST00000908325, ENST00000908326, ENST00000908327, ENST00000908328, ENST00000908329, ENST00000908330, ENST00000908331, ENST00000908332, ENST00000908333, ENST00000908334, ENST00000908335, ENST00000908336, ENST00000908337, ENST00000908338, ENST00000908339, ENST00000908340, ENST00000908341, ENST00000908342, ENST00000908343, ENST00000908344, ENST00000908345, ENST00000918784, ENST00000918785, ENST00000918786, ENST00000918787, ENST00000918788, ENST00000918789, ENST00000918790, ENST00000918791, ENST00000918792, ENST00000918793, ENST00000918794, ENST00000918795, ENST00000918796, ENST00000918797, ENST00000918798, ENST00000918799, ENST00000918800, ENST00000918801, ENST00000918802, ENST00000918803, ENST00000918804, ENST00000918805, ENST00000918806, ENST00000918807, ENST00000918808, ENST00000918809, ENST00000918810, ENST00000918811, ENST00000918812, ENST00000918813, ENST00000918814, ENST00000918815, ENST00000918816, ENST00000918817, ENST00000918818, ENST00000918819, ENST00000918820, ENST00000970647, ENST00000970648, ENST00000970649, ENST00000970650, ENST00000970651, ENST00000970652, ENST00000970653, ENST00000970654, ENST00000970655, ENST00000970656, ENST00000970657, ENST00000970658

RefSeq mRNA: 16 — MANE Select: NM_012286 NM_001142418, NM_001142419, NM_001142420, NM_001142421, NM_001142422, NM_001142423, NM_001142424, NM_001142425, NM_001142426, NM_001142427, NM_001142428, NM_001142429, NM_001142430, NM_001142431, NM_001142432, NM_012286

CCDS: CCDS14512

Canonical transcript exons

ENST00000441076 — 4 exons

Exon	Start	End
ENSE00001105620	103678499	103678651
ENSE00001381796	103685171	103685260
ENSE00001836859	103686631	103686699
ENSE00001886847	103675498	103677051

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 234.9215 / max 7866.7275, expressed in 1826 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200009	205.3306	1826
200011	23.1451	1782
200008	2.3922	1123
200012	1.6175	965
200010	0.8434	442
200006	0.8117	431
200004	0.6496	352
200005	0.1314	35

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	99.80	gold quality
choroid plexus epithelium	UBERON:0003911	99.77	gold quality
bronchial epithelial cell	CL:0002328	99.69	gold quality
pons	UBERON:0000988	99.69	gold quality
caput epididymis	UBERON:0004358	99.69	gold quality
cauda epididymis	UBERON:0004360	99.69	gold quality
postcentral gyrus	UBERON:0002581	99.66	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.66	gold quality
seminal vesicle	UBERON:0000998	99.64	gold quality
parietal lobe	UBERON:0001872	99.64	gold quality
corpus epididymis	UBERON:0004359	99.63	gold quality
superior vestibular nucleus	UBERON:0007227	99.63	gold quality
epithelium of bronchus	UBERON:0002031	99.61	gold quality
bronchus	UBERON:0002185	99.61	gold quality
tibia	UBERON:0000979	99.57	gold quality
endometrium	UBERON:0001295	99.56	gold quality
adult organism	UBERON:0007023	99.56	gold quality
decidua	UBERON:0002450	99.53	gold quality
saphenous vein	UBERON:0007318	99.52	gold quality
myometrium	UBERON:0001296	99.51	gold quality
entorhinal cortex	UBERON:0002728	99.50	gold quality
frontal pole	UBERON:0002795	99.50	gold quality
pericardium	UBERON:0002407	99.48	gold quality
orbitofrontal cortex	UBERON:0004167	99.48	gold quality
ovary	UBERON:0000992	99.47	gold quality
mammary duct	UBERON:0001765	99.47	gold quality
medulla oblongata	UBERON:0001896	99.47	gold quality
left ovary	UBERON:0002119	99.47	gold quality
right ovary	UBERON:0002118	99.46	gold quality
middle temporal gyrus	UBERON:0002771	99.46	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	74.51
E-GEOD-134144	yes	35.42
E-MTAB-6678	yes	17.46
E-MTAB-7316	yes	13.24
E-HCAD-11	yes	6.83
E-HCAD-9	yes	6.28
E-MTAB-6819	no	3022.42
E-HCAD-5	no	1358.42
E-MTAB-8381	no	503.13
E-MTAB-10287	no	43.90
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

104 targeting MORF4L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-3180-5P	99.82	69.12	2422

Literature-anchored findings (GeneRIF, showing 5)

• can repress or activate the B-myb promoter depending on the cell type studied, suggesting that there may be tissue-specific functions of this protein (PMID:14506250)
• The transcriptional status of four key genes, thymidylate synthase (TYMS), MORF-related gene X (MRGX), Bcl2-antagonist/killer (BAK), and ATPase, Cu(2+) transporting beta polypeptide (ATP7B), can accurately predict response to 5-FU. (PMID:18593893)
• Suberoylanilide hydroxamic acid enhanced the expression of malignant genes such as MORF4L2 in lung cancer cells remaining after treatment, creating a more drug-resistant state. (PMID:25796627)
• Identification of hub genes in unstable atherosclerotic plaque by conjoint analysis of bioinformatics. (PMID:33011223)
• miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2. (PMID:35900839)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Morf4l2	ENSMUSG00000031422
rattus_norvegicus	Morf4l2	ENSRNOG00000002389
rattus_norvegicus	RGD1564748	ENSRNOG00000066849
drosophila_melanogaster	MRG15	FBGN0027378

Paralogs (3): MSL3 (ENSG00000005302), MORF4L1 (ENSG00000185787), MSL3B (ENSG00000293137)

Protein

Protein identifiers

Mortality factor 4-like protein 2 — Q15014 (reviewed: Q15014)

Alternative names: MORF-related gene X protein, Protein MSL3-2, Transcription factor-like protein MRGX

All UniProt accessions (4): Q15014, Q5JXX1, Q5JXX2, Q5JXX6

UniProt curated annotations — full annotation on UniProt →

Function. Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histone H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when directly recruited to sites of DNA damage. Also a component of the MSIN3A complex which acts to repress transcription by deacetylation of nucleosomal histones.

Subunit / interactions. Component of the NuA4 histone acetyltransferase complex which contains the catalytic subunit KAT5/TIP60 and the subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, MORF4L2/MRGX, MRGBP, YEATS4/GAS41 and VPS72/YL1. The NuA4 complex interacts with MYC and the adenovirus E1A protein. MORF4L1 may also participate in the formation of NuA4 related complexes which lack the KAT5/TIP60 catalytic subunit, but which include the SWI/SNF related protein SRCAP. Component of the MSIN3A histone deacetylase complex, which includes SIN3A, HDAC2, ARID4B, MORF4L1, RBBP4/RbAp48, and RBBP7/RbAp46. Interacts with MRFAP1 and RB1. May also interact with one or more as yet undefined members of the TLE (transducin-like enhancer of split) family of transcriptional repressors.

Subcellular location. Nucleus.

RefSeq proteins (16): NP_001135890, NP_001135891, NP_001135892, NP_001135893, NP_001135894, NP_001135895, NP_001135896, NP_001135897, NP_001135898, NP_001135899, NP_001135900, NP_001135901, NP_001135902, NP_001135903, NP_001135904, NP_036418* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008676	MRG	Family
IPR026541	MRG_dom	Domain
IPR038217	MRG_C_sf	Homologous_superfamily

Pfam: PF05712

UniProt features (7 total): mutagenesis site 2, chain 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15014-F1	74.12	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 71

Mutagenesis-validated functional residues (2):

Position	Phenotype
132–136	abrogates both transcriptional activation and repression by morf4l2.
263	abrogates both transcriptional activation and repression by morf4l2.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization

MSigDB gene sets: 313 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_REGULATION_OF_DNA_RECOMBINATION, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, TGCGCANK_UNKNOWN, MORF_RAB5A, AAGTCCA_MIR422B_MIR422A, GCANCTGNY_MYOD_Q6, CMYB_01, SP3_Q3, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MORF_RAD21, HSIAO_HOUSEKEEPING_GENES

GO Biological Process (9): DNA repair (GO:0006281), chromatin organization (GO:0006325), regulation of apoptotic process (GO:0042981), positive regulation of DNA-templated transcription (GO:0045893), regulation of cell cycle (GO:0051726), positive regulation of double-strand break repair via homologous recombination (GO:1905168), regulation of double-strand break repair (GO:2000779), regulation of DNA-templated transcription (GO:0006355), DNA damage response (GO:0006974)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): nucleosome (GO:0000786), nucleoplasm (GO:0005654), nucleolus (GO:0005730), plasma membrane (GO:0005886), NuA4 histone acetyltransferase complex (GO:0035267), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Chromatin organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
nuclear lumen	2
DNA metabolic process	1
DNA damage response	1
cellular component organization	1
apoptotic process	1
regulation of programmed cell death	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cell cycle	1
regulation of cellular process	1
double-strand break repair via homologous recombination	1
regulation of double-strand break repair via homologous recombination	1
positive regulation of DNA recombination	1
positive regulation of double-strand break repair	1
regulation of DNA repair	1
double-strand break repair	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cellular response to stress	1
binding	1
chromatin	1
protein-DNA complex	1
cellular anatomical structure	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
H4/H2A histone acetyltransferase complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2198 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MORF4L2	MRGBP	Q9NV56	991
MORF4L2	KAT5	Q92993	891
MORF4L2	TRRAP	Q9Y4A5	856
MORF4L2	BRD8	Q9H0E9	762
MORF4L2	YEATS4	O95619	686
MORF4L2	MEAF6	Q9HAF1	674
MORF4L2	ING3	Q9NXR8	639
MORF4L2	DMAP1	Q9NPF5	626
MORF4L2	KAT6B	Q8WYB5	602
MORF4L2	MRFAP1	Q9Y605	586
MORF4L2	HDAC1	Q13547	574
MORF4L2	UBXN7	O94888	500
MORF4L2	MBTD1	Q05BQ5	472
MORF4L2	KAT7	O95251	470
MORF4L2	MSL3	Q8N5Y2	458

IntAct

312 interactions, top by confidence:

A	B	Type	Score
MRFAP1	MORF4L2	psi-mi:“MI:0915”(physical association)	0.950
MORF4L2	MRFAP1	psi-mi:“MI:0915”(physical association)	0.950
MRGBP	MORF4L2	psi-mi:“MI:0915”(physical association)	0.940
MORF4L2	MRGBP	psi-mi:“MI:0915”(physical association)	0.940
MRFAP1L1	MORF4L2	psi-mi:“MI:0915”(physical association)	0.830
MORF4L2	MRFAP1L1	psi-mi:“MI:0915”(physical association)	0.830
H2AZ1	ZNHIT1	psi-mi:“MI:0914”(association)	0.770
MBTD1	YEATS4	psi-mi:“MI:0914”(association)	0.730
MBTD1	MORF4L2	psi-mi:“MI:0914”(association)	0.730
MORF4L2	CEP55	psi-mi:“MI:0915”(physical association)	0.720
DDIT4L	MORF4L2	psi-mi:“MI:0915”(physical association)	0.720
MORF4L2	DDIT4L	psi-mi:“MI:0915”(physical association)	0.720
MORF4L2	ZBTB43	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (342): MORF4L2 (Two-hybrid), MORF4L2 (Two-hybrid), MORF4L2 (Two-hybrid), MORF4L2 (Two-hybrid), MORF4L2 (Two-hybrid), TNIP1 (Two-hybrid), IKZF1 (Two-hybrid), PNMA2 (Two-hybrid), ZBTB43 (Two-hybrid), KLHL3 (Two-hybrid), ZBTB7B (Two-hybrid), THAP1 (Two-hybrid), CEP55 (Two-hybrid), MRGBP (Two-hybrid), GRAMD3 (Two-hybrid)

ESM2 similar proteins: A5A6J5, D4AB66, E2RSQ2, F1M5F3, F1N2W9, F1QDI9, I0IUP4, O14795, P17863, P22681, P22682, P49797, Q02040, Q15014, Q24K03, Q2KHI9, Q2KJ58, Q2T9Y1, Q2YDJ8, Q496Y0, Q4KUS2, Q4R578, Q52L14, Q56K12, Q5C9Z4, Q5F3L9, Q5M7C8, Q5R6Y9, Q5R905, Q62768, Q62769, Q66JB6, Q69ZT9, Q6QI89, Q8BND4, Q8BZ60, Q8HXH0, Q8IYS8, Q8N5Y2, Q8VDV3

Diamond homologs: A5A6J5, A7DTF0, G3X992, O13953, P0C860, P0CO86, P0CO87, P60762, Q12432, Q15014, Q4P827, Q4R578, Q4V3E2, Q4WPW2, Q54RM0, Q59K07, Q5BBV4, Q5NVP9, Q5R6Y9, Q5R905, Q6AYG1, Q6AYU1, Q6BT38, Q6C9M9, Q6CND0, Q6QI89, Q75AH9, Q8N5Y2, Q94C32, Q9R0Q4, Q9UBU8, Q9WVG9, Q9Y0I1, P50536, Q9NBL2, A2CG63, F8VPQ2, P29374, Q4LE39, Q6FN68

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MORF4L2	“form complex”	“NuA4 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 80 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HATs acetylate histones	6	11.6×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of double-strand break repair	7	59.0×	1e-08
positive regulation of double-strand break repair via homologous recombination	7	38.9×	1e-07
chromatin organization	8	11.5×	4e-05
regulation of apoptotic process	9	10.9×	2e-05
regulation of cell cycle	8	8.7×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

35 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	19
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
253519	GRCh37/hg19 Xq22.2(chrX:102774255-103167770)x3	Pathogenic
58664	GRCh38/hg38 Xq22.1-22.3(chrX:101620923-107632397)x3	Pathogenic
816375	GRCh37/hg19 Xq22.2(chrX:102742391-103109211)x2	Pathogenic

SpliceAI

793 predictions. Top by Δscore:

Variant	Effect	Δscore
X:103685164:CACTT:C	donor_loss	1.0000
X:103685165:ACTT:A	donor_loss	1.0000
X:103685166:CTTAC:C	donor_loss	1.0000
X:103685167:TTACC:T	donor_loss	1.0000
X:103685168:TAC:T	donor_loss	1.0000
X:103685169:A:AC	donor_gain	1.0000
X:103685169:AC:A	donor_gain	1.0000
X:103685170:C:CC	donor_gain	1.0000
X:103685170:C:CT	donor_loss	1.0000
X:103685170:CC:C	donor_gain	1.0000
X:103677049:CCA:C	acceptor_gain	0.9900
X:103677050:CA:C	acceptor_gain	0.9900
X:103677050:CAC:C	acceptor_gain	0.9900
X:103677052:C:CC	acceptor_gain	0.9900
X:103678497:A:AC	donor_gain	0.9900
X:103678498:C:CC	donor_gain	0.9900
X:103678498:CA:C	donor_gain	0.9900
X:103684440:TGAA:T	donor_gain	0.9900
X:103685170:CCCAA:C	donor_gain	0.9900
X:103685257:TGAC:T	acceptor_gain	0.9900
X:103685261:C:CC	acceptor_gain	0.9900
X:103685262:T:A	acceptor_loss	0.9900
X:103685270:C:CT	acceptor_gain	0.9900
X:103685274:C:CT	acceptor_gain	0.9900
X:103686653:C:A	donor_gain	0.9900
X:103687983:TCTTA:T	donor_loss	0.9900
X:103687986:TACCT:T	donor_loss	0.9900
X:103678506:T:TA	donor_gain	0.9800
X:103684439:TTGAA:T	donor_gain	0.9800
X:103685169:ACC:A	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000076182 (X:103689865 G>T), RS1000131845 (X:103689191 A>G), RS1000515063 (X:103677776 T>A), RS1001132002 (X:103686707 G>A), RS1001336362 (X:103686396 G>A), RS1001401639 (X:103678670 A>G), RS1001449081 (X:103686843 C>T), RS1001920448 (X:103687880 G>A), RS1002569340 (X:103684767 T>C), RS1002775225 (X:103688518 A>G), RS1003009945 (X:103683825 T>C), RS1003093421 (X:103682065 A>G), RS1003145793 (X:103681546 A>AT), RS1003451958 (X:103681990 C>T), RS1003841795 (X:103688164 C>G,T)

Disease associations

OMIM: gene MIM:300409 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST90002389_496	Lymphocyte percentage of white cells	4.000000e-12
GCST90002395_643	Mean platelet volume	4.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007993	lymphocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation	3
bisphenol A	affects cotreatment, increases methylation, decreases expression	2
chloropicrin	affects expression, decreases expression	2
Rotenone	decreases expression, increases expression	2
Dronabinol	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
methylparaben	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	increases expression	1
entinostat	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Azacitidine	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Catechin	affects cotreatment, increases expression	1
Copper	affects binding, increases expression	1
Coumestrol	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1DV	Abcam HCT 116 MORF4L2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.